Senzime’s TetraGraph supported by new European clinical guidelines for patient monitoring
The European Society of Anaesthesiology and Intensive Care (ESAIC) strongly recommends the use of quantitative neuromuscular monitoring to prevent complications related to muscle relaxants. Senzime’s TetraGraph® system fulfills these new guidelines, offering increased patient safety and less complications.
Uppsala, November 16, 2022. Senzime AB (publ) today announced that guidelines from the European Society of Anaesthesiology and Intensive Care (ESAIC), which is the leading European organization for anesthesia, intensive care, pain and perioperative medicine, have been published in the European Journal of Anaesthesiology. This is the first time that ESAIC has presented guidelines in this field, now strongly recommends the use of quantitative neuromuscular monitoring.
Every year, more than 80 million surgeries are done globally where patients receive paralytic drugs (NMBAs) as part of anesthesia. National clinical guidelines are increasingly mandating the use of objective and quantitative patient monitoring when paralytic drugs are used to avoid complications and ensure patient safety. The new clinical guidelines from ESAIC, Peri-operative management of neuromuscular blockade – A guideline from the European Society of Anaesthesiology and Intensive Care, include strong recommendations of using quantitative neuromuscular monitoring and to continue using this type of technology until a Train-of-Four (TOF) ratio greater than 0.9 (90 percent) has been achieved. Senzime’s product TetraGraph enables this by following a patient until the muscle recovery exceeds 90 percent, supporting neuromuscular blockade management from start to finish.
“The new European guidelines from ESAIC are yet another major milestone and supportive evidence for Senzime’s unique products, solutions, and vision. Our TetraGraph system is developed entirely in line with the technology now recommended by the leading European organization for anesthesia. These guidelines, in combination with the recently presented American guidelines, will certainly accelerate the use of quantitative monitoring in the operating room and drive the roll-out of Tetragraph to help improve patient safety throughout the world,” said Pia Renaudin, CEO of Senzime.
TetraGraph is a quantitative neuromuscular monitor, based on the gold standard electromyography (EMG) technology which provides accurate and versatile monitoring of neuromuscular blockade. The product is designed to meet the needs of monitoring physiological data during surgery of patients receiving general anesthesia and muscle relaxation using muscle paralyzing drugs. TetraGraph stimulates the patient's peripheral nerve using the TetraSens disposable sensors and measures, analyzes, and displays muscle function in real time. Thanks to its small size and versatile features, TetraGraph can be used in any type of surgery, anywhere in the hospital environment, and can be connected to external monitors and electronic hospital records.
Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.
Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.